On November 8, 2019 AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, reported that new data from its ongoing Phase 2 clinical trial in glioblastoma multiforme will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting by Lead Principal Investigator Dr. Daniela Bota (Press release, AIVITA Biomedical, NOV 8, 2019, View Source [SID1234550754]). The podium presentation will detail early encouraging survival data, immune response data and tumor biomarker and imaging data. Details for the oral presentation are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Meeting: Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting
Presenter: Dr. Daniela Bota, MD, PhD, University of California, Irvine; AIVITA GBM Lead Principal Investigator
Title: Phase II trial of therapeutic vaccine consisting of autologous dendritic cells loaded with autologous tumor cell antigens from self-renewing cancer cells in patients with newly diagnosed glioblastoma
Session: Session 311: A Tale of Two Brain Tumors: Primary versus Metastatic CNS Tumors
When: 6:15 PM ET, Saturday Nov 9
Location: Gaylord National Hotel & Convention Center, National Harbor, MD